These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15532993)

  • 1. CpG-DNA as immune response modifier.
    Dalpke AH; Heeg K
    Int J Med Microbiol; 2004 Oct; 294(5):345-54. PubMed ID: 15532993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in immunostimulatory CpG oligonucleotides.
    Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
    Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural requirements for uptake and recognition of CpG oligonucleotides.
    Heeg K; Dalpke A; Peter M; Zimmermann S
    Int J Med Microbiol; 2008 Jan; 298(1-2):33-8. PubMed ID: 17706458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the development of immunostimulatory oligonucleotides.
    Uhlmann E; Vollmer J
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of lipoteichoic acid and CpG-DNA during activation of innate immune cells.
    Dalpke AH; Frey M; Morath S; Hartung T; Heeg K
    Immunobiology; 2002 Oct; 206(4):392-407. PubMed ID: 12437070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
    Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
    Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
    Mutwiri G
    Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
    Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
    Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
    Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
    Front Immunol; 2019; 10():179. PubMed ID: 30800129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential signaling by CpG DNA in DCs and B cells: not just TLR9.
    Verthelyi D; Zeuner RA
    Trends Immunol; 2003 Oct; 24(10):519-22. PubMed ID: 14552833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
    Whitmore MM; DeVeer MJ; Edling A; Oates RK; Simons B; Lindner D; Williams BR
    Cancer Res; 2004 Aug; 64(16):5850-60. PubMed ID: 15313929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptors: cellular signal transducers for exogenous molecular patterns causing immune responses.
    Kirschning CJ; Bauer S
    Int J Med Microbiol; 2001 Sep; 291(4):251-60. PubMed ID: 11680785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immunostimulatory phosphodiester oligodeoxynucleotides with CpT sequences instead of CpG motifs.
    Kim D; Jung J; Lee Y; Kwon HJ
    Mol Immunol; 2011 Jul; 48(12-13):1494-504. PubMed ID: 21529949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG-oligonucleotides in vaccination: signaling and mechanisms of action.
    Dalpke A; Zimmermann S; Heeg K
    Immunobiology; 2001 Dec; 204(5):667-76. PubMed ID: 11846232
    [No Abstract]   [Full Text] [Related]  

  • 19. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens.
    Andersen JM; Al-Khairy D; Ingalls RR
    Biol Reprod; 2006 May; 74(5):824-31. PubMed ID: 16421230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopharmacology of CpG DNA.
    Dalpke A; Zimmermann S; Heeg K
    Biol Chem; 2002 Oct; 383(10):1491-500. PubMed ID: 12452427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.